Is the hormonal fountain of youth drying up?

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 59, Issue 5, 2004, Pages 458-460

  Morley, John E ^a  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PRASTERONE; VITAMIN D;

AGING; EDITORIAL; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; PRIORITY JOURNAL; TESTOSTERONE METABOLISM; VITAMIN D METABOLISM; VITAMIN METABOLISM;

EID: 2442424038     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/59.5.m458     Document Type: Editorial

References (80)

1. Morley JE. Hormones and the aging process. J Am Geriatr Soc. 2003;51(7 Suppl S):S333-S337.
2. Morley JE. Growth hormone: fountain of youth or death hormone? J Am Geriatr Soc. 1999;47:1475-1476.
3. Villareal DT, Morley JE. Trophic factors in aging - should older people receive hormonal replacement therapy. Drugs Aging. 1994;4:492-509.
4. Banks WA, Morley JE. Endocrine and metabolic changes in human aging. J Am Aging Assoc. 2000;23:103-115.
5. Morley JE, Perry HM. Andropause: an old concept in new clothing. Clin Geriatr Med. 2003;19:507-528.
6. Morley JE, Perry HM. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol. 2003;85:367-373.
7. Morley JE. Andropause: is it time for the geriatrician to great it? J Gerontol Med Sci. 2001;56A:M263-M265.
8. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol Med Sci. 2002;57A:M76-M99.
9. Morley JE, Perry HM. Androgens and women at the menopause and beyond. J Gerontol Med Sci. 2003;58A:409-416.
10. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women - the Women's Health Initiative Memory Study. A randomized controlled trial. JAMA. 2003;289:2651-2662.
11. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function and postmenopausal women - the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
12. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women - the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
13. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854.
14. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy - scientific review. JAMA. 2002;288:872-881.
15. Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc. 1985;33:800-807.
16. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1-6.
17. Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-1 concentrations. Clin Endocrinol. 1993;39:417-425.
18. Bartke A, Coshigano K, Kopchick J, et al. Genes that prolong life: relationships of growth hormone and growth to aging and life span. J Gerontol Biol Sci. 2001;56A:B340-B349.
19. Morley JE. Growth hormone. Sci Geriatr. 2000;1/2:263-271.
20. Dozmorov I, Galecki A, Chang YY, Krzesicki R, Vergara M, Miller RA. Gene expression profile of long-lived snell dwarf mice. J Gerontol Biol Sci. 2002;57A:B99-B108.
21. Carter CS, Ramsey MM, Ingram RL, et al. Models of growth hormone and IGF-1 deficiency: applications to studies of aging processes and life-span determination. J Gerontol Biol Sci. 2002;57A:B177-B188.
22. Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc. 1991;39:235-240.
23. Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is dependent on nitric oxide. Peptides. 2003;24:913-918.
24. Perry HM, Horowitz M, Morley JE, Patrick P, Vellas B, Baumgartner R, Garry PJ. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metab Clin Exper. 1999;48:1028-1032.
25. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-1642.
26. Visser M, Deeg DJM, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia). J Clin Endocrinol Metab. 2003;88:5766-5772.
27. Zamboni M, Zoico E, Tosoni P, et al. Relation between vitamin D, physical performance, and disability in elderly persons. J Gerontol Med Sci. 2002;57A:M7-M11.
28. Bischoff HA, Stahelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil. 1999;80:54-58.
29. Pfeifer M, Begerow BB, Minne HW, et al. Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 post-menopausal women with osteoporosis. Exp Clin Endocrinol Diabetes. 2001;109:87-92.
30. Dhesi JK, Beame LM, Moniz C, et al. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res. 2002;17:891-897.
31. Gloth FM, Smith CE, Hollis BW, Tobin JD. Functional improvement with vitamin D replenishment in a cohort of frail, vitamin D-deficient older people. J Am Geriatr Soc. 1995;43:1269-1271.
32. Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging. 2000;12:455-460.
33. Kenny AM, Biskuup B, Robbins B, Marcella G, Barleson JA. Effects of vitamin D supplementation on strength, physical function and health perception in older, community-dwelling men. J Am Geriatr Soc. 2003;12:1762-1767.
34. Flood JF, Morley JE, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A. 1992;89:1567-1571.
35. Flood JF, Roberts E. Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res. 1988;448:178-181.
36. Flood JF, Smith GE, Roberts E. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res. 1988;447:269-278.
37. Valenti G, Denti L, Maggio M, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol Med Sci. 2004;59A:466-472.
38. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000;97:4279-4284.
39. Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60-to 80-year-old individuals on muscle function and cross-sectional area - a double-blind placebo-controlled trial. Arch Intern Med. 2003;163:720-727.
40. Wolkowitz OM, Kramer JH, Reus VI, et al. DHEA treatment of Alzheimer's disease - a randomized, double-blind, placebo-controlled study. Neurology. 2003;60:1071-1076.
41. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
42. Asthana S. Estrogen and cognition: the story so far. J Gerontol Med Sci. 2003;58A:322-323.
43. Whitmer RA, Haan MN, Miller JW, Yaffe K. Hormone replacement therapy and cognitive performance: the role of homocysteine. J Gerontol Med Sci. 2003;58A:324-330.
44. Petitti DB, Buckwalter G, Crooks VC, Chiu V. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data. J Gerontol Med Sci. 2002;57A:M532-M538.
45. McNeal MC, Zareparsi S, Camicioli R, et al. Predictors of healthy brain aging. J Gerontol Biol Sci. 2001;56A:B294-B301.
46. Watkins RA, Guariglia R, Kaye JA, Janowsky JS. Informants' knowledge of reproductive history and estrogen replacement. J Gerontol Med Sci. 2001;56A:M176-M179.
47. Ott BR, Belazi D, Lapane KL. Cognitive decline among female estrogen users in nursing homes. J Gerontol Med Sci. 2002;57A:M594-M598.
48. Farr SA, Flood JF, Scherrer JF, Kaiser FE, Taylor GT, Morley JE. Effect of ovarian steroids on footshock avoidance learning and retention in female mice. Physiol Behav. 1995;58:715-723.
49. Anderson JK, Faulkner S, Cranor C, Briley J, Gevirtz F, Roberts S. Andropause: knowledge and perceptions among the general public and health care professionals. J Gerontol Med Sci. 2002;57A:M793-M796.
50. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Med Sci. 2003;58A:618-625.
51. Morley JE. The need for a men's health initiative. J Gerontol Med Sci. 2003;58:614-617.
52. Lambert CP, Sullivan DH, Evans WJ. Megestrol acetate-induced weight gain does not negatively affect blood lipids in elderly men: effects of resistance training and testosterone replacement. J Gerontol Med Sci. 2003;58A:644-647.
53. Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol Med Sci. 2003;58:165-170.
54. Christmas C, O'Connor KG, Harman SM, et al. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontol Med Sci. 2002;57A: M12-M18.
55. Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2002;57A:M460-M465.
56. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2002;57A:M321-M325.
57. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2001;56A:M266-M272.
58. Morley JE, Perry HM. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med. 2000;135:370-378.
59. Sih R, Morley JE, Kaiser Fe, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men - a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661-1667.
60. Morley JE. Testosterone and behavior. Clin Geriatr Med. 2003;19:605-616.
61. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol Med Sci. 2003;58A:1002-1008.
62. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol Med Sci. 2003;58A:1103-1110.
63. Asthana S, Bhasin S, Butler RN, et al. Masculine vitality: pros and cons of testosterone in treating the andropause. J Gerontol Med Sci. 2004;59A:461-465.
64. Liverman CT, Blazer D. Testosterone and Aging: Clinical Research Directions. Institute of Medicine. Washington DC: National Academy Press. 2003:1-270.
65. Morley JE. The metabolic syndrome and aging. J Gerontol Med Sci. 2004;59A:139-142.
66. Morley JE, Perry HM, Baumgartner RP, Garry PJ. Commentary: leptin, adipose tissue and aging - is there a role for testosterone? J Gerontol Biol Sci. 1999;54A:B108-B109.
67. Olshansky SJ, Hayflick L, Carnes BA. Position statement on human aging. J Gerontol Biol Sci. 2002;57A:B292-B297.
68. Butler RN, Fossel M, Harman SM, et al. Is there an antiaging medicine? J Gerontol Biol Sci. 2002;57A:B333-B338.
69. Fisher A, Morley JE. Antiaging medicine: the good, the bad, and the ugly. J Gerontol Med Sci. 2002;57A:M636-M639.
70. Morley JE. Mobility performance: a high-tech test for geriatricians. J Gerontol Med Sci. 2003;58A:712-714.
71. Thomas DR. The relationship between functional status and inflammatory disease in older adults. J Gerontol Med Sci. 2003;58A:995-998.
72. Lan TY, Deeg DJH, Guralnik JM, Melzer D. Responsiveness of the index of mobility limitation: comparison with gait speed alone in the longitudinal aging study Amsterdam. J Gerontol Med Sci. 2003;58:721-727.
73. Bean JF, Leveille SG, Kiely DK, Bandinelli S, Guralnik JM, Ferrucci L. A comparison of leg power and leg strength within the InCHIANTI study: which influences mobility more? J Gerontol Med Sci. 2003;58A:728-733.
74. Morley JE, Perry HM, Miller DK. Something about frailty. J Gerontol Med Sci. 2002;57A:M698-M704.
75. Bean JF, Kiely DK, Leveille SG, et al. The 6-minute walk test in mobility-limited elders: what is being measured? J Gerontol Med Sci. 2002;57A:M751-M756.
76. Lord SR, Murray SM, Chapman K, Munro B, Tiedemann A. Sit-to-stand performance depends on sensation, speed, balance, and psychological status in addition to strength in older people. J Gerontol Med Sci. 2002;57A:M539-M543.
77. Bortz WM. A conceptual framework of frailty: a review. J Gerontol Med Sci. 2002;57A:M283-M288.
78. Lan TY, Melzer D, Tom BDM, Guralnik JM. Performance tests and disability: developing an objective index of mobility-related limitation in older populations. J Gerontol Med Sci. 2002;57A:M294-M301.
79. Lipsitz LA. Dynamics of stability: the physiological basis of functional health and frailty. J Gerontol Biol Sci. 2002;57A:B115-B125.
80. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci. 2001;56A:M146-M156.